Definition of Local Recurrence Site in Resected Pancreatic Adenocarcinoma: A Multicenter Study (DOLORES-1).
Kernel density estimation
adjuvant chemoradiation
pancreatic neoplasms
pattern of failure
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Jun 2021
18 Jun 2021
Historique:
received:
05
05
2021
revised:
09
06
2021
accepted:
15
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
The study aimed to generate a local failure (LF) risk map in resected pancreatic cancer (PC) and validate the results of previous studies, proposing new guidelines for PC postoperative radiotherapy clinical target volume (CTV) delineation. Follow-up computer tomography (CT) of resected PC was retrospectively reviewed by two radiologists identifying LFs and plotting them on a representative patient CT scan. The percentages of LF points randomly extracted based on CTV following the RTOG guidelines and based on the LF database were 70% and 30%, respectively. According to the Kernel density estimation, an LF 3D distribution map was generated and compared with the results of previous studies using a Dice index. Among the 64 resected patients, 59.4% underwent adjuvant treatment. LFs closer to the root of the celiac axis (CA) or the superior mesenteric artery (SMA) were reported in 32.8% and 67.2% cases, respectively. The mean (± standard deviation) distances of LF points to CA and SMA were 21.5 ± 17.9 mm and 21.6 ± 12.1 mm, respectively. The Dice values comparing our iso-level risk maps corresponding to 80% and 90% of the LF probabilistic density and the CTVs-80 and CTVs-90 of previous publications were 0.45-0.53 and 0.58-0.60, respectively. According to the Kernel density approach, a validated LF map was proposed, modeling a new adjuvant CTV based on a PC pattern of failure.
Identifiants
pubmed: 34207481
pii: cancers13123051
doi: 10.3390/cancers13123051
pmc: PMC8234595
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Gastrointest Surg. 2006 Apr;10(4):511-8
pubmed: 16627216
Stat Med. 2018 Mar 30;37(7):1191-1221
pubmed: 29226352
J Clin Oncol. 2008 Jul 20;26(21):3511-6
pubmed: 18640932
Ann Surg. 2006 Aug;244(2):332-3; author reply 333
pubmed: 16858208
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer. 2013 Jun 15;119(12):2350-7
pubmed: 23625519
Cancer. 1976 Mar;37(3):1519-24
pubmed: 1260670
Lancet. 2001 Nov 10;358(9293):1576-85
pubmed: 11716884
Cancer. 1999 Feb 1;85(3):583-90
pubmed: 10091731
Langenbecks Arch Surg. 2012 Aug;397(6):927-32
pubmed: 22382704
Crit Rev Oncol Hematol. 2016 Feb;98:309-24
pubmed: 26653573
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):901-8
pubmed: 22483737
JAMA. 2007 Jan 17;297(3):267-77
pubmed: 17227978
J Clin Oncol. 2009 Apr 10;27(11):1806-13
pubmed: 19273710
Radiat Oncol. 2016 Oct 19;11(1):138
pubmed: 27756417
Adv Radiat Oncol. 2020 Aug 26;5(6):1197-1205
pubmed: 33305081
Ann Surg. 2007 Nov;246(5):734-40
pubmed: 17968163
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):911-7
pubmed: 25220717
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1007-15
pubmed: 24267969
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):809-16
pubmed: 21277694
Arch Surg. 1985 Aug;120(8):899-903
pubmed: 4015380
Cancer. 1987 Jun 15;59(12):2006-10
pubmed: 3567862
Cancers (Basel). 2020 Jun 29;12(7):
pubmed: 32610592
BMC Cancer. 2019 Jun 11;19(1):569
pubmed: 31185957
N Engl J Med. 2004 Mar 18;350(12):1200-10
pubmed: 15028824
Cancer. 1990 Jul 1;66(1):56-61
pubmed: 2354408
BMC Med Imaging. 2015 Aug 12;15:29
pubmed: 26263899
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4
pubmed: 10615932